FCG
STLN

Fielder Capital Group’s Starling Oncology STLN Stock Holding History

Fielder Capital Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Hold
70,192
– – 0.08% 173
2026
Q1 		$215K Hold
70,192
– – 0.05% 267
2025
Q4 		$250K Hold
70,192
– – 0.05% 230
2025
Q3 		$245K Hold
70,192
– – 0.06% 212
2025
Q2 		$144K Hold
70,192
– – 0.04% 235
2025
Q1 		$80K Hold
70,192
– – 0.02% 223
2024
Q4 		$21.7K Hold
70,192
– – 0.01% 212
2024
Q3 		$22.9K Hold
70,192
– – 0.01% 214
2024
Q2 		$32.3K Hold
70,192
– – 0.01% 196
2024
Q1 		$111K Hold
70,192
– – 0.05% 169
2023
Q4 		$143K Buy
+70,192
New +$122K 0.09% 142

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fielder Capital Group's STLN Position: Q2 2026 in Review

Fielder Capital Group held its Starling Oncology (STLN) position steady in Q2 2026 at 70,192 shares worth $381K. The position accounts for 0.08% of the portfolio, ranked #173.

Fielder Capital Group first reported a position in STLN in Q4 2023 and has held it in 11 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Fielder Capital Group held 70,192 shares of Starling Oncology worth $381K as of Q2 2026.
  • Fielder Capital Group left its Starling Oncology share count unchanged in Q2 2026.
  • Starling Oncology made up 0.08% of Fielder Capital Group's portfolio in Q2 2026, its #173 holding.
  • Fielder Capital Group first reported a position in Starling Oncology in Q4 2023 and has held it in 11 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Fielder Capital Group's 13F filing for Q2 2026, filed 6 Aug 2026.